Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710513 | 0.74 | DYRK1A (0.40) | DYRK1AHTTKMT2ADAO | |
| SCHEMBL13695116 | 0.74 | LMNA (0.37) | DYRK1AHTTKMT2ADAO | |
| SCHEMBL29431111 | 0.74 | HTT (0.35) | HTTKMT2A | |
| SCHEMBL20536281 | 0.74 | HTT (0.40) | HTTKMT2A | |
| SCHEMBL22831886 | 0.73 | DYRK1A (0.38) | DYRK1A | |
| Ammonia Solution, Strong SCHEMBL6481862 | 0.72 | PLAU (0.38) | DYRK1ADAO | |
| SCHEMBL6222367 | 0.71 | FYN (0.38) | DYRK1A | |
| SCHEMBL23944916 | 0.70 | HTT (0.31) | HTTKMT2A | |
| SCHEMBL31240890 | 0.70 | LMNA (0.41) | DYRK1AHTTKMT2ADAO | |
| SCHEMBL3668940 | 0.70 | DYRK1A (0.36) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-03-21 | — | — | US | disclosed |
| CN-110072865-B | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2009112473-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112473-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | DYRK1A 226/4885HTT 4362/4885KMT2A 472/4885 |
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | BTK, SYK, ITK | DYRK1A 1041/4885HTT 2709/4885KMT2A 1967/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | DYRK1A 349/4885HTT 4627/4885KMT2A 1524/4885 |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | DYRK1A 1041/4885HTT 2709/4885KMT2A 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.